KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31

Kiniksa Pharmaceuticals International, plc

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026

$79.48+0.89 (+1.13%)

Close on Oct 19, 2026

Market cap: $6.63B
P/E (TTM): 81.9
Dividend yield: –

Kiniksa Pharmaceuticals International, plc income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31
Revenue	678	423	270	220	39	–	–	–	–
Cost of Revenue	78	61	33	23	9.10	–	–	–	–
Gross Profit	600	362	237	197	29	–	–	–	–
Research & Development	97	112	76	65	99	112	135	87	56
Selling, General & Admin	196	168	129	98	86	45	35	–	–
General & Administrative	–	–	–	–	–	45	35	22	9.04
Advertising Expenses	12	11	9.07	5.73	–	–	–	–	–
Operating Expenses	–	–	–	–	–	157	170	108	65
Operating Income	77	-46	-25	9.77	-157	-157	-170	-108	-65
Interest & Investment Income	12	9.04	8.23	1.23	0.10	1.13	6.05	4.72	0.53
Asset Impairment Charges	0	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	0.12	0.02	-0.18	-0.03	-0.10	–	-0.02	-0.07	–
Pretax Income	89	-36	-17	11	-157	-156	-164	-103	-65
Income Tax Expense	30	7.04	-31	-172	1.39	5.15	-2.05	-0.21	0.00
Net Income incl. Noncontrolling Interests	59	-43	14	183	-158	-161	-162	-103	-65
Net Income	59	-43	14	183	-158	-161	-162	-103	-65
EPS (Basic)(per share)	0.80	-0.60	0.20	2.64	-2.30	-2.61	-2.99	-3.49	-35.85
EPS (Diluted)(per share)	0.75	-0.60	0.20	2.60	-2.30	-2.61	-2.99	-3.49	-35.85
Shares Outstanding (Basic, Weighted)(shares)	74	71	70	69	69	62	54	30	1.81
Shares Outstanding (Diluted, Weighted)(shares)	79	71	72	70	69	62	54	30	1.81
EBITDA	79	-44	-23	12	-154	-155	-168	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 89.8%
Operating margin: 11.9%
Net margin: 9.6%
Return on equity, FY2025: 11.7%

Financial strength

Current ratio: 3.90
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 102.6%

Valuation

P/E ratio: 81.9
Price to sales: 7.88
Price to book: 10.13
Dividend yield: –